|
May 14
|
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
|
|
May 13
|
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
|
|
Apr 25
|
Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year
|
|
Apr 24
|
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
|
|
Apr 23
|
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
|
|
Apr 2
|
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B...
|
|
Mar 21
|
Q4 2023 BioNTech SE Earnings Call
|
|
Mar 17
|
Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
Autolus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
|
|
Mar 15
|
Q4 2023 Autolus Therapeutics PLC Earnings Call
|
|
Mar 14
|
Autolus Therapeutics PLC Reports Full Year 2023 Financial Results
|
|
Mar 14
|
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
|
|
Mar 12
|
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
|
|
Mar 11
|
Autolus Therapeutics announces publication in Blood Cancer Journal
|
|
Feb 1
|
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
|
|
Jan 22
|
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
|
|
Jan 11
|
We're Not Very Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Rate
|
|
Jan 10
|
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
|
|
Dec 22
|
Autolus Therapeutics Announces Changes to its Board of Directors
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|